The Importance of Rapid Methods for Pathogen Identification and Antibiotic Resistance Mechanism Detection for Optimization of Antibiotic Therapy: A Narrative Review

Antibiotic resistance represents one of the pressing challenges of contemporary clinical practice, as it contributes to increased mortality, prolonged hospitalization, and a growing economic burden on healthcare systems. This problem is of particular significance in infections caused by ESKAPE pathogens, carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa, for which the timely selection of rational antibacterial therapy directly affects prognosis. The aim of the present review is to synthesize current evidence on the value of rapid methods for pathogen identification and antibiotic resistance mechanism detection in optimizing antibiotic therapy. The literature search was conducted in PubMed/MEDLINE, eLibrary, CyberLeninka, Google Scholar, Springer Link, and ScienceDirect; a total of 70 publications were included in the analysis. The capabilities of multiplex PCR panels, MALDI-TOF MS, rapid phenotypic antimicrobial susceptibility testing methods, metagenomic sequencing, and ancillary biomarkers are examined. It has been demonstrated that rapid diagnostics can shorten the time to appropriate therapy, accelerate escalation upon detection of resistant strains, facilitate de-escalation, and reduce unnecessary antibiotic use. The most pronounced clinical effect is achieved when rapid diagnostic tests are integrated into antimicrobial stewardship programs involving microbiologists, clinical pharmacologists, and infectious disease specialists. At the same time, data on the impact of rapid diagnostics on mortality rates, length of hospital stay, and economic costs remain heterogeneous, which is attributable to local epidemiological indicators, the availability of technologies, the organization of laboratory workflows, and the quality of clinical interpretation of results.

1. Kumar Sharma H, Singh R, Grover A, Malik R, Triveni, Singh S, et al. Estimating the disease burden of drug-resistant bacterial infections: present trends and future risks. In: Hospital-Acquired Infections — Bridging Pathogen Challenges to Sustainable Healthcare Solutions [Internet]. London: IntechOpen; 2025. doi: https://doi.org/10.5772/intechopen.1012085. https://www.intechopen.com/online-first/1231286.

2. Morozov AM, Sergeev AN, Kadykov VA, Askerov EM, Zhukov SV, Minakova YuE, et al. O razvitii antibiotikorezistentnosti v aspekte poliklinicheskoi sluzhby. Vestnik Sovremennoi Klinicheskoi Meditsiny. 2021; 14 (5): 43–50. (In Russ.). doi: https://doi.org/10.20969/VSKM.2021.14(5).43-50.

3. Ugleva SV, Starodubov VI, Beregovykh VV, Akimkin VG, Kozlov RS, Tutelyan AV, et al. Antibiotic resistance is a Russia’s most important challenge: scientific and practical aspects, solutions. Annals of the Russian Academy of Medical Sciences. 2024; 79 (6): 539–550. (In Russ.). doi: https://doi.org/10.15690/vramn17922.

4. Karpov OE, Gusarov VG, Zamyatin MN, Orlova OA, Petrova LV, Kamyshova DA, et al. Upravlenie antibiotikorezistentnost’yu v statsionare: sovremennye realii i perspektivy. Klinicheskaya Mikrobiologiya i Antimikrobnaya Khimioterapiya. 2020; 22 (4): 277–286. (In Russ.)]. doi: https://doi.org/10.36488/cmac.2020.4.277-286.

5. Alshaikh A, Kubas M. Empirical antibiotic use, resistance patterns, and their impact on clinical outcomes in a Yemeni tertiary hospital. New Microbes New Infect. 2026; 101723. doi: 10.1016/j.nmni.2026.101723.

6. Ohnuma T, Chihara S, Costin B, et al. Association of appropriate empirical antimicrobial therapy with in-hospital mortality in patients with bloodstream infections in the US. JAMA Netw Open. 2023; 6 (1): e2249353. doi: 10.1001/jamanetworkopen.2022.49353.

7. Urzedo JE, de Paula Menezes R, Ferreira ML, de Brito CS, Dantas RCC, Gontijo-Filho PP, et al. Inappropriate empirical antimicrobial treatment in bloodstream infections patients in the era of multidrug resistance. Rev Epidemiol Control Infect. 2022; 12 (2): 55–60. doi: https://doi.org/10.17058/reci.v12i2.16855. https://www.researchgate.net/publication/366631132_Inappropriate_empirical_antimicrobial_treatment_in_bloodstream_infections_patients_in_the_era_of_multidrug_resistance

8. Eidelstein MV, Shaidullina ER, Ivanchik NV, Dekhnich AV, Mikotina AV, Skleenova EYu, et al. Antimicrobial resistance of clinical isolates of Klebsiella pneumoniae and Escherichia coli in Russian hospitals: results of a multicenter epidemiological study. Klinicheskaya Mikrobiologiya i Antimikrobnaya Khimioterapiya. 2024; 26 (1): 67–78. (In Russ.). doi: https://doi.org/10.36488/cmac.2024.1.67-78.

9. Matuszak SS, Kolodziej L, Micek S, Kollef M. Antibiotic de-escalation in the intensive care unit: rationale and potential strategies. Antibiotics (Basel). 2025; 14 (5): 467. doi: 10.3390/antibiotics14050467.

10. Zeitler K, Narayanan N. The present and future state of antimicrobial stewardship and rapid diagnostic testing: can one ideally succeed without the other? Curr Treat Options Infect Dis. 2019; 11: 177–187. doi: 10.1007/s40506-019-00190-9.

11. Tanzarella ES, Cutuli SL, Lombardi G, Cammarota F, Caroli A, Franchini E, et al. Antimicrobial de-escalation in critically ill patients. Antibiotics. 2024; 13 (4): 375. doi: 10.3390/antibiotics13040375.

12. de Klerk P, Zikalala-Mabope LA, Skosana PP. Determining the use and reasons for non-de-escalation of empiric carbapenem therapy in a private hospital in South Africa. Antibiotics (Basel). 2025; 14 (12): 1220. doi: 10.3390/antibiotics14121220.

13. Kassis I, Al Balas M, Rashid SH, et al. Appropriateness of antibiotic therapy and its association with clinical outcomes among critically ill patients: a retrospective study from the United Arab Emirates. Research Square [Preprint]. 2026 Jan 27. doi: 10.21203/rs.3.rs-8481307/v1.

14. Rodríguez-Gómez M, Martínez-Sagasti F, Calle-Romero M, PrietoCabrera A, De La Montaña-Díaz P, Díaz-De la Torre I, et al. RAPIDCARE: rapid antibiotic optimization in the ICU after implementation of a pneumonia multiplex PCR test — a real-world evaluation. Antibiotics (Basel). 2025; 14 (11): 1084. doi: 10.3390/antibiotics14111084.

15. Gigante V, Sati H, Beyer P. Recent advances and challenges in antibacterial drug development. ADMET DMPK. 2022; 10 (2): 147–151. doi: 10.5599/admet.1271.

16. Gigante V, Alm RA, Melchiorri D, Rocke T, Arias CA, Czaplewski L, et al. Multi-year analysis of the global preclinical antibacterial pipeline: trends and gaps. Antimicrob Agents Chemother. 2024; 68: e00535–24. doi: 10.1128/aac.00535-24.

17. Catalano A, Iacopetta D, Ceramella J, Pellegrino M, Giuzio F, Marra M, et al. Antibiotic-resistant ESKAPE pathogens and COVID-19: the pandemic beyond the pandemic. Viruses. 2023; 15 (9): 1843. doi: 10.3390/v15091843.

18. Warwas FB, Thol F, Sieber MA, et al. Next-generation sequencing improves pathogen identification in odontogenic abscesses, could this affect clinical outcomes? Clin Oral Investig. 2025; 29: 430. doi: 10.1007/s00784-025-06504-0.

19. Aguilar-Salazar A, Martínez-Vázquez AV, Aguilera-Arreola G, de Jesus de Luna-Santillana E, Cruz-Hernández MA, Escobedo-Bonilla CM, et al. Prevalence of ESKAPE bacteria in surface water and wastewater sources: multidrug resistance and molecular characterization, an updated review. Water. 2023;15 (18): 3200. doi: 10.3390/w15183200.

20. Salim MA, Diler SB, Köklü R, Öztrük A, Polat F, Hajhamed NM, et al. Prevalence and drug resistance patterns of ESKAPE pathogens in Nigde, Türkiye. J Infect Dev Ctries. 2026; 20 (02): 208–218. doi: 10.3855/jidc.21781.

21. Alvisi G, Curtoni A, Fonnesu R, Piazza A, Signoretto C, Piccinini G, et al. Epidemiology and genetic traits of carbapenemase-producing Enterobacterales: a global threat to human health. Antibiotics. 2025; 14 (2): 141. doi: 10.3390/antibiotics14020141.

22. Bansal J, Goel V, Pal N, Singh K, Manocha H, Sahni AK. Trends of carbapenem resistance in Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacterales in a tertiary care hospital. Indian J Microbiol Trop Dis. 2025. doi: 10.18231/j.ijmmtd.2025.034.

23. Singla S, Murk FNU, Singla B, Lama S, Fareed MU, Anika NN, et al. Enhancing bloodstream infection management: a systematic review of rapid diagnostic tests and their integration into antimicrobial stewardship programs. Cureus. 2025; 17 (9): e92866. doi: 10.7759/cureus.92866.

24. Wolk DM, Parrott JS, Babady NE, Mochon AB, Tom R, Diel C, et al. The American Society for Microbiology’s evidence-based laboratory medicine practice guidelines for the diagnosis of bloodstream infections using rapid tests: a systematic review and meta-analysis. Clin Microbiol Rev. 2025; 38: e0013724. doi: 10.1128/cmr.00137-24.

25. Peri AM, Chatfield MD, Ling W, Furuya-Kanamori L, Harris PNA, Paterson DL. Rapid diagnostic tests and antimicrobial stewardship programs for the management of bloodstream infection: what is their relative contribution to improving clinical outcomes? A systematic review and network meta-analysis. Clin Infect Dis. 2024; 79 (2): 502–515. doi: 10.1093/cid/ciae234.

26. Pintea-Simon IA, Bancu L, Mare AD, Ciurea CN, Toma F, Man A. Rapid molecular diagnostics of pneumonia caused by Gram-negative bacteria: a clinician’s review. Antibiotics (Basel). 2024; 13 (9): 805. doi: 10.3390/antibiotics13090805.

27. Butler MS, Gigante V, Sati H, Paulin S, Al-Sulaiman L, Rex JH, et al. Analysis of the clinical pipeline of treatments for drug-resistant bacterial infections: despite progress, more action is needed. Antimicrob Agents Chemother. 2022; 66 (3): e0199121. doi: 10.1128/aac.01991-21.

28. Mahrous NN, Fallatah MM, Fitaihi RA, Aldahshan H, Alhhazmi AA, Al-Khaldi S, et al. Point-of-care diagnostic technologies for antimicrobial resistance: principles, platforms, clinical impact, and future directions. Diagnostics. 2026; 16 (8): 1239. doi: 10.3390/diagnostics16081239.

29. Caspar Y, Deves A, Richarme C, Le Marechal M, Ponderand L, Mounayar A-L, et al. Clinical impact and cost-consequence analysis of ePlex® blood culture identification panels for the rapid diagnosis of bloodstream infections: a single-center randomized controlled trial. Eur J Clin Microbiol Infect Dis. 2024; 43: 1193–1203. doi: 10.1007/s10096-024-04820-z.

30. Bryant S, Almahmoud I, Pierre I, Bardet J, Touati S, Maubon D, et al. Evaluation of microbiological performance and the potential clinical impact of the ePlex® blood culture identification panels for the rapid diagnosis of bacteremia and fungemia. Front Cell Infect Microbiol. 2020; 10: 594951. doi: 10.3389/fcimb.2020.594951.

31. Verroken A, Despas N, Rodriguez-Villalobos H, Laterre PF. The impact of a rapid molecular identification test on positive blood cultures from critically ill patients with bacteremia: a pre-post intervention study. PLoS One. 2019; 14 (9): e0223122. doi: 10.1371/journal.pone.0223122.

32. Claeys KC, Heil EL, Hitchcock S, Johnson JK, Leekha S. Management of Gram-negative bloodstream infections in the era of rapid diagnostic testing: impact with and without antibiotic stewardship. Open Forum Infect Dis. 2020; 7 (10): ofaa427. doi: 10.1093/ofid/ofaa427.

33. Grant JM, Porter C, Charles MK, Bryce EA, Wong T, Stefanovic A, et al. Potential influence of rapid diagnostics on timeliness of management decisions for patients with positive blood cultures. Off J Assoc Med Microbiol Infect Dis Can. 2019; 5 (1): 21–28. doi: 10.3138/jammi.2019-0002.

34. Beganovic M, McCreary EK, Mahoney MV, Dionne B, Green DA, Timbrook TT. Interplay between rapid diagnostic tests and antimicrobial stewardship programs among patients with bloodstream and other severe infections. J Appl Lab Med. 2019; 3 (4): 601–616. doi: 10.1373/jalm.2018.026450.

35. Adolph JE, Pentek C, Bauch T, Held C, Brenner T, Felderhoff-Müser U, et al. Next-generation sequencing of cell-free microbial DNA in blood samples of critically ill children: a single-center experience. Mol Cell Pediatr. 2026; 13: 12. doi: 10.1186/s40348-026-00226-3.

36. Thol F, Warwas FB, Spuck N, Kramer F-J, Heim N. Microbial spectrum and resistance of odontogenic abscesses — microbiological analysis using next generation sequencing. Clin Oral Investig. 2025; 29: 8. doi: 10.1007/s00784-024-06097-0.

37. Lin B, Meng X, Pu K, Fu T, Peng N, Li Q. Early diagnostic strategy for central nervous system bacterial infections after neurosurgery: a retrospective study. Medicine. 2025; 104 (51): e46635. doi: 10.1097/MD.0000000000046635.

38. Curren EJ, Lutgring JD, Kabbani S, Diekema DJ, Gitterman S, Lautenbach E, et al. Advancing diagnostic stewardship for healthcareassociated infections, antibiotic resistance, and sepsis. Clin Infect Dis. 2022; 74 (4): 723–728. doi: 10.1093/cid/ciab672.

39. Simons CC, Capraro GA. Barriers to implementation of rapid identification and antimicrobial susceptibility testing technologies in the clinical microbiology laboratory: an American perspective. J Antimicrob Chemother. 2024; 79 (Suppl 1): i32–i36. doi: 10.1093/jac/dkae279.

40. Raycheva R, Lengerova G, Petrov M, Kantardjiev T. Rapid diagnostic testing in bloodstream infections: a retrospective clinical and economic evaluation from a university hospital in Bulgaria. Microorganisms. 2026; 14 (3): 675. doi: 10.3390/microorganisms14030675.

41. Wang L, Yang F, Zhou C, Yang X, Rong J, Chi X, et al. Multifactorial impacts of blood culture process optimization on clinical outcomes and healthcare economics in bloodstream infection management. Front Cell Infect Microbiol. 2026; 16: 1699905. doi: 10.3389/fcimb.2026.1699905.

42. Ehren K, Meißner A, Jazmati N, Wille J, Jung N, Vehreschild JJ, et al. Clinical impact of rapid species identification from positive blood cultures with same-day phenotypic antimicrobial susceptibility testing on the management and outcome of bloodstream infections. Clin Infect Dis. 2020; 70 (7): 1285–1293. doi: 10.1093/cid/ciz406.

43. Dubinina YuN, Sarzhevskii VO, Mel’nichenko VYa, Mochkin NE. Primenenie biomarkerov vospaleniya dlya prognoza infektsionnykh oslozhnenii posle autologichnoi transplantatsii gemopoeticheskikh stvolovykh kletok. Onkogematologiya. 2025; 20 (3): 104–119. (In Russ.)]. doi: https://doi.org/10.17650/1818-8346-2025-20-3-104-119.

44. Eubank TA, Long SW, Perez KK. Role of rapid diagnostics in diagnosis and management of patients with sepsis. J Infect Dis. 2020; 222 (Suppl 2): S103–S109. doi: 10.1093/infdis/jiaa263.

45. Cheng J, Li Q, Zhang G, Xu H, Li Y, Tian X, et al. Time to appropriate antibiotic therapy is an independent indicator of poor outcome in children with nosocomial Klebsiella pneumoniae bloodstream infection. Research Square [Preprint]. 2021. doi: 10.21203/rs.3.rs-136343/v1.

46. Kramme E, Käding N, Graf T, Schmoll K, Linnen H, Nagel K, et al. Rapid diagnostic testing combined with an immediate infectious disease consultation increases the rate of septic intensive care unit patients on targeted antibiotic therapy. Front Cell Infect Microbiol. 2025; 14: 1513408. doi: 10.3389/fcimb.2024.1513408.

47. Banerjee R, Patel R. Molecular diagnostics for genotypic detection of antibiotic resistance: current landscape and future directions. JAC Antimicrob Resist. 2023; 5 (1): dlad018. doi: 10.1093/jacamr/dlad018.

48. Marin KC, Ritiu SA, Băloi A, Barsac CR, Sandesc D, Papurica M, et al. Rapid molecular diagnostics for MDR nosocomial infections in ICUs: integration with prevention, stewardship, and novel therapies. Diagnostics. 2025; 15 (23): 3060. doi: 10.3390/diagnostics15233060.

49. Liborio MP, Peri AM, Harris PNA. Evaluating emerging molecular diagnostics for severe infections in neutropenic patients with hematological malignancies. Expert Rev Mol Diagn. 2026; 26 (4): 345–361. doi: 10.1080/14737159.2026.2667917.

50. Raycheva R, Lengerova G, Petrov M, Kantardjiev T. Clinical and economic value of rapid microbiological diagnostics in bloodstream infections: a state-of-the-art evidence review with emphasis on PCR and MALDI-TOF. Microorganisms. 2026; 14 (5): 994. doi: 10.3390/microorganisms14050994.

51. Jinks T, Subramaniam S, Bassetti M, Gales AC, Kullar R, Metersky ML, et al. Opportunities to enhance diagnostic testing and antimicrobial stewardship: a qualitative multinational survey of healthcare professionals. Infect Dis Ther. 2024; 13 (7): 1621–1637. doi: 10.1007/s40121-024-00996-1.

52. Moore LSP, Villegas MV, Wenzler E, Ramson TM, Oladele RO, Apisarnthanarak A. Rapid diagnostic test value and implementation in antimicrobial stewardship across low-to-middle and high-income countries: a mixed-methods review. Infect Dis Ther. 2023; 12: 1445–1463. doi: 10.1007/s40121-023-00815-z.

53. Dona D, Barbieri E, Brigadoi G, Barchitta M, Berardi A, Bosis S, et al. Pediatric stewardship in Italy: a necessity, not an option — a National Multi-Society Expert Consensus on Antimicrobial and Diagnostic Stewardship (SIP, SITIP, SIMRI, SIAIP, SIMEUP, SIPPS, SICUPP, SIMIT, SIMPE, SIPINF, SIT, SIAATIP, SARNEPI, AIEOP, SIM, SITI, SIF, SIFACT, SITA, SIN). Ital J Pediatr. 2025;51:283. doi: 10.1186/s13052-025-02112-6.

54. Comini S, Bianco G, Boattini M, Banche G, Ricciardelli G, Allizond V, et al. Evaluation of a diagnostic algorithm for rapid identification of Gram-negative species and detection of extended-spectrum β-lactamase and carbapenemase directly from blood cultures. J Antimicrob Chemother. 2022; 77 (10): 2632–2641. doi: 10.1093/jac/dkac230.

55. Tiseo G, Arena F, Borrè S, Campanile F, Falcone M, Mussini C, et al. Diagnostic stewardship based on patient profiles: differential approaches in acute versus chronic infectious syndromes. Expert Rev Anti Infect Ther. 2021; 19 (11): 1373–1383. doi: 10.1080/14787210.2021.1926986.

56. Di Marcello A, Santoro A, Todisco V, Franceschini E, Orlando G, Casolari S, et al. Proactive antimicrobial stewardship with real-time microbiological alerts improves management of bloodstream infections. JAC Antimicrob Resist. 2025; 7 (5): dlaf182. doi: 10.1093/jacamr/dlaf182.

57. Pokharel S, White LJ, Sacks JA, Escadafal C, Toporowski A, Mohammed SI, et al. Two-test algorithms for infectious disease diagnosis: implications for COVID-19. PLOS Glob Public Health. 2022; 2 (3): e0000293. doi: 10.1371/journal.pgph.0000293.

58. Rodríguez A, Gómez F, Sarvisé C, Gutiérrez C, Giralt MG, GuerreroTorres MD, et al. Clinical and microbiological impact of implementing a decision support algorithm through microbiologic rapid diagnosis in critically ill patients: an epidemiological retrospective pre-/postintervention study. Biomedicines. 2023; 11 (12): 3330. doi: 10.3390/biomedicines11123330.

59. Mponponsuo K, Leal J, Spackman E, Somayaji R, Gregson D, RennertMay E. Mathematical model of the cost-effectiveness of the BioFire FilmArray Blood Culture Identification (BCID) Panel molecular rapid diagnostic test compared with conventional methods for identification of Escherichia coli bloodstream infections. J Antimicrob Chemother. 2022; 77 (2): 507–516. doi: 10.1093/jac/dkab398.

60. Wang F, Zhan Q, Zhu H, Guo L, Shu L, Qu T. Non-genitourinary Ureaplasma urealyticum infections in solid organ transplant recipients: a case report and literature review. BMC Infect Dis. 2025; 25: 1827. doi: 10.1186/s12879-025-12223-4.

61. Donà D, Barbieri E, Brigadoi G, Liberati C, Bosis S, Castagnola E, et al. State of the art of antimicrobial and diagnostic stewardship in pediatric setting. Antibiotics. 2025; 14 (2): 132. doi: 10.3390/antibiotics14020132.

62. Elbehiry A, Marzouk E, Abalkhail A, Anagreyyah S, Almalki A, Alazwari N, et al. Rapid molecular diagnostics for bloodstream infection in patients with chronic kidney disease. Diagnostics. 2026; 16 (8): 1156. doi: 10.3390/diagnostics16081156.

63. Apisarnthanarak A, Kim HB, Moore L, et al. Rapid diagnostic testing for antimicrobial stewardship: utility in Asia Pacific. Infect Control Hosp Epidemiol. 2021; 42 (7): 864–868. doi: 10.1017/ice.2021.149.

64. Lengerova G, Raycheva R, Petrov M, Kantardjiev T. Balancing speed and cost: economic insights from rapid diagnostic testing in bloodstream infections. Antibiotics (Basel). 2026; 15 (3): 320. doi: 10.3390/antibiotics15030320.

65. Lau TMM, Daniel R, Hughes K, Wootton M, Hood K, Gillespie D. A systematic review investigating the use of microbiology outcome measures in randomized controlled trials evaluating antimicrobial stewardship interventions published between 2011 and 2021. JAC Antimicrob Resist. 2022; 4 (1):dlac013. doi: 10.1093/jacamr/dlac013.

66. Bykov AO, Suvorova MP, Protsenko DN, Yakovlev SV,Ignatenko OV, Burmistrova EN, et al. Analiz struktury bakteriemii i chuvstvitel’nosti k antibiotikam mikroorganizmov, vydelennykh v otdeleniyakh reanimatsii i intensivnoi terapii v skoropomoshchnom statsionare v period s 2003 po 2021 g.: retrospektivnoe nablyudatel’noe issledovanie. Vestnik Intensivnoi Terapii Imeni AI Saltanova. 2023; (2): 55–65. (In Russ.)]. doi: https://doi.org/10.21320/1818-474X-2023-2-55-65.

67. Vasin RV, Filimonov VB, Tereshchenko SV, Ionov EN. Urinary tract infections. Experience of City Clinical Hospital No. 11 Ryazan. Retrospective laboratory monitoring data for 2022. Experimental and Clinical Urology. 2024; 17 (1): 110–117. (In Russ.)]. doi: https://doi.org/10.29188/2222-8543-2024-17-1-110-117.

68. Gordeeva SA, Zolotarev AYu, Movsisyan MG, Rozinko AV. Experience with the use of microbiological analyzer BactoSCREEN in a routine practice of clinical microbiology laboratory. Klinicheskaya Mikrobiologiya i Antimikrobnaya Khimioterapiya. 2020; 22 (3): 221–230. (In Russ.). doi: https://doi.org/10.36488/cmac.2020.3.221-230.

69. Barantsevich NE, Barantsevich EP. Use of Sanger sequencing in etiological diagnostics of bacterial complications in hospital environment. Antibiot Khimioter = Antibiotics and Chemotherapy. 2024; 69 (9–10): 17–23. (In Russ.). doi: https://doi.org/10.37489/0235-2990-2024-69-9-10-17-23.

70. Bazanovich SA, Yuryev MYu, Gudozhnikova VV, Zhdanova MA, Golubeva MA, Petrova MV, Kameneva TR. Analysis of bacteremia profiles in patients with chronic critical illness undergoing treatment and rehabilitation in intensive care units. Fizicheskaya i Reabilitatsionnaya Meditsina, Meditsinskaya Reabilitatsiya. 2025; 7 (3): 190–200. (In Russ.). doi: https://doi.org/10.36425/rehab690041.